{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:57:28Z","timestamp":1780088248538,"version":"3.54.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Recent studies show that blocking CD47-SIRP\u03b1 interactions is a promising target in checkpoint inhibition for cancer immunotherapy. However, to date, the expression of CD47 is not well characterized in various hematolymphoid neoplasms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study evaluates CD47 expression in a wide range of hematolymphoid neoplasms using immunohistochemistry on 834 cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Results show variable but widespread CD47 expression among tumor types and within individual samples in both intensity and percentage. The highest CD47 expressions in both percentage of positive lymphoma cells and intensity was seen in small B-cell lymphomas, particularly chronic lymphocytic leukemia\/small lymphocytic lymphoma, mantle cell, marginal zone, and follicular lymphomas. T and B lymphoblastic, diffuse large B-cell, peripheral T-cell, \u03b3\u03b4 T-cell, angioimmunoblastic T-cell lymphomas and myelodysplastic syndrome showed moderate CD47 expression. Acute and chronic myeloid leukemia as well as classic Hodgkin, anaplastic large cell, and natural killer\/T-cell lymphomas showed low expression. Burkitt lymphoma is a notable standout, with little to no CD47 expression in all 14 cases examined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Understanding the prevalence of CD47 expression in hematolymphoid neoplasms is crucial for identifying potential therapeutic targets and selecting patients who may benefit from CD47-targeted therapies. Additionally, CD47 may serve as a valuable diagnostic marker in neoplasms such as Burkitt lymphoma.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqaf018","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T13:29:21Z","timestamp":1741786161000},"page":"883-897","source":"Crossref","is-referenced-by-count":4,"title":["Expression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy"],"prefix":"10.1093","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7287-2842","authenticated-orcid":false,"given":"Jingjing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Colorado Anschutz Medical Campus , Aurora, CO ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-743X","authenticated-orcid":false,"given":"Philip L","family":"Bulterys","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University , Stanford, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0428-0199","authenticated-orcid":false,"given":"Sebastian","family":"Fernandez-Pol","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University , Stanford, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheren F","family":"Younes","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University , Stanford, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchun","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University , Stanford, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Mansoor","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-1018","authenticated-orcid":false,"given":"Yasodha","family":"Natkunam","sequence":"additional","affiliation":[{"name":"Department of Pathology, Stanford University , Stanford, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025060500015540000_CIT0001","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell."},{"key":"2025060500015540000_CIT0002","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol."},{"key":"2025060500015540000_CIT0003","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell."},{"key":"2025060500015540000_CIT0004","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell."},{"key":"2025060500015540000_CIT0005","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med."},{"key":"2025060500015540000_CIT0006","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","article-title":"Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia","volume":"71","author":"Chao","year":"2011","journal-title":"Cancer Res."},{"key":"2025060500015540000_CIT0007","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1002\/jcp.30163","article-title":"Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells","volume":"236","author":"Wang","year":"2021","journal-title":"J Cell Physiol."},{"key":"2025060500015540000_CIT0008","doi-asserted-by":"publisher","first-page":"D871","DOI":"10.1093\/nar\/gkm861","article-title":"The Stanford tissue microarray database","volume":"36","author":"Marinelli","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"2025060500015540000_CIT0009","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","article-title":"Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy","volume":"19","author":"Barkal","year":"2018","journal-title":"Nat Immunol."},{"key":"2025060500015540000_CIT0010","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.humpath.2018.06.034","article-title":"Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies","volume":"82","author":"Devereaux","year":"2018","journal-title":"Hum Pathol."},{"key":"2025060500015540000_CIT0011","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1182\/blood-2006-08-039024","article-title":"The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas","volume":"109","author":"Natkunam","year":"2007","journal-title":"Blood."},{"key":"2025060500015540000_CIT0012","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1182\/blood-2021-152071","article-title":"Upregulation of CD47 expression in De Novo diffuse large B-cell lymphoma is more frequent in activated B-cell type","volume":"138","author":"Lee","year":"2021","journal-title":"Blood."},{"key":"2025060500015540000_CIT0013","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRP\u03b1 requires Fc-Fc\u03b3R interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood."},{"key":"2025060500015540000_CIT0014","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1111\/cas.14437","article-title":"Combination of CD47 and signal-regulatory protein-\u03b1 constituting the \u201cdon\u2019t eat me signal\u201d is a prognostic factor in diffuse large B-cell lymphoma","volume":"111","author":"Kazama","year":"2020","journal-title":"Cancer Sci."},{"key":"2025060500015540000_CIT0015","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood."},{"key":"2025060500015540000_CIT0016","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv."},{"key":"2025060500015540000_CIT0017","doi-asserted-by":"publisher","first-page":"e004984","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J ImmunoTher Cancer."},{"key":"2025060500015540000_CIT0018","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.164793","article-title":"Hyperprogression of cutaneous T-cell lymphoma after anti-PD-1 treatment","volume":"8","author":"Gao","year":"2023","journal-title":"JCI Insight."},{"key":"2025060500015540000_CIT0019","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood."},{"key":"2025060500015540000_CIT0020","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3324\/haematol.2023.283154","article-title":"CD47 expression in acute myeloid leukemia varies according to genotype","volume":"108","author":"Marra","year":"2023","journal-title":"Haematologica."},{"key":"2025060500015540000_CIT0021","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.leukres.2015.04.007","article-title":"CD47 protein expression in acute myeloid leukemia: a tissue microarray-based analysis","volume":"39","author":"Galli","year":"2015","journal-title":"Leuk Res."},{"key":"2025060500015540000_CIT0022","doi-asserted-by":"publisher","first-page":"CT037","DOI":"10.1158\/1538-7445.am2024-ct037","article-title":"Abstract CT037: a phase I investigator-initiated trial of evorpacept (ALX148), lenalidomide and rituximab for patients with relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"84","author":"Strati","year":"2024","journal-title":"Cancer Res."},{"key":"2025060500015540000_CIT0023","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1200\/JCO.2023.41.16_suppl.7527","article-title":"Preliminary results from a phase I\/II study of IMM0306, a CD47 and CD20 bispecific monoclonal antibody-trap, in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin\u2019s lymphoma","volume":"41","author":"Yang","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025060500015540000_CIT0024","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv."},{"key":"2025060500015540000_CIT0025","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/hon.3009","article-title":"Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma","volume":"40","author":"Li","year":"2022","journal-title":"Hematol Oncol."},{"key":"2025060500015540000_CIT0026","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood.2021014485","article-title":"Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL","volume":"140","author":"M\u00fcller","year":"2022","journal-title":"Blood."},{"key":"2025060500015540000_CIT0027","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/6\/883\/62385620\/aqaf018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/163\/6\/883\/62385620\/aqaf018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:02:01Z","timestamp":1749096121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/163\/6\/883\/8071625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaf018","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,12]]}}}